0001209191-23-009232.txt : 20230214 0001209191-23-009232.hdr.sgml : 20230214 20230214170854 ACCESSION NUMBER: 0001209191-23-009232 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230210 FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanna Bastiano CENTRAL INDEX KEY: 0001829069 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 23631401 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-10 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001829069 Sanna Bastiano C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Cell & Genetic Therapies Common Stock 2023-02-10 4 F 0 902 294.33 D 66368 D Common Stock 2023-02-13 4 F 0 4340 298.26 D 62028 D Common Stock 2023-02-13 4 S 0 113 300.39 D 61915 D Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $300.39 (range $300.00 to $300.79). /s/ Christiana Stevenson, Attorney-in-Fact 2023-02-14